Supplemental Table 2. Activity of ASO targeting RBD or BCL-xL in B16F10, A375 and 132N1 cells

ABSTRACT

Aims: To
investigate the distribution, tolerance, and anticancer/antiviral activity of
Zn-based physiometacomposites (PMCs).
Methods: Manganese, iron, nickel and cobalt doped ZnO, ZnS or ZnSe were
synthesized. Cell uptake, distribution into 3-D culture and mice, biochemical
and chemotherapeutic activity were studied by fluorescence/bioluminescence,
confocal microscopy, flow cytometry, viability, antitumor and virus titer
assays. Results: Luminescence and
inductively coupled plasma mass spectrometry analysis showed that
nanoparticle distribution was liver>spleen>kidney>lung>brain,
without tissue or blood pathology. Photophysical characterization as ex
vivo tissue probes and LL37 peptide, antisense oligomer (ASO) or aptamer
delivery targeting RAS/RBD. 25 µg/ml 48-hour treatment showed >98-99%
cell viability, 3-D organoid uptake, 3-log inhibition of β-Galactosidase and
porcine reproductive respiratory virus infection. Conclusions: Data support the preclinical development of PMCs for
imaging and delivery targeting cancer and infectious disease.